Development of Malignant Hyperthermia Obscured by Cardiopulmonary Bypass

Overview

Journal Can Anaesth Soc J

Specialty Anesthesiology

Date 1986 Jul 1

PMID 3742327

Citations 6

Authors

R G MacGillivray

H Jann

E Vanker

L Gemmell

A E Mahomedy

Affiliations

Soon will be listed here.

Abstract

An episode of malignant hyperthermia occurring in a two-year-old child undergoing cardiac surgery is reported. The coincidental usage of hypothermic cardiopulmonary bypass obscured the classical presenting signs and symptoms of the syndrome. Once the clinical diagnosis was confirmed, rapid reversal was achieved with the administration of dantrolene sodium.

Citing Articles

Anti-adrenergic agents and the risk of postoperative acute kidney injury.

Asakawa S, Shibata S Hypertens Res. 2023; 47(3):796-798.

PMID: 38135846 DOI: 10.1038/s41440-023-01546-x.

Successful management of hypothermic cardiopulmonary bypass in a malignant hyperthermia susceptible patient.

Agarwal S, Graham K, Kigwana S, Castresana M Ann Card Anaesth. 2020; 23(3):367-371.

PMID: 32687103 PMC: 7559943. DOI: 10.4103/aca.ACA_245_18.

Malignant Hyperthermia: Report of Two Cases with a Neglected Complication in Cardiac Surgery.

Neshati M, Azadeh M, Neshati P, Burnett T, Saenz R, Karbasi B J Tehran Heart Cent. 2018; 12(4):175-183.

PMID: 29576786 PMC: 5849591.

Rare postoperative delayed malignant hyperthermia after off-pump coronary bypass surgery and brief review of literature.

Raut M, Kar S, Maheshwari A, Shivnani G, Kumar A, Daniel E Ann Card Anaesth. 2016; 19(2):357-62.

PMID: 27052086 PMC: 4900359. DOI: 10.4103/0971-9784.179620.

Massive rhabdomyolysis following cardiopulmonary bypass.

Kim Y, Yoon Y, Kim J, Baek W Korean J Thorac Cardiovasc Surg. 2014; 47(2):181-4.

PMID: 24782976 PMC: 4000883. DOI: 10.5090/kjtcs.2014.47.2.181.

References

Britt B . Dantrolene. Can Anaesth Soc J. 1984; 31(1):61-75. DOI: 10.1007/BF03011484. View

Kurlan R, Hamill R, Shoulson I . Neuroleptic malignant syndrome. Clin Neuropharmacol. 1984; 7(2):109-20. DOI: 10.1097/00002826-198406000-00001. View

Sladen R . Temperature and ventilation after hypothermic cardiopulmonary bypass. Anesth Analg. 1985; 64(8):816-20. View

Britt B . Malignant hyperthermia. Can Anaesth Soc J. 1985; 32(6):666-78. DOI: 10.1007/BF03011418. View

Nelson T, Flewellen E . Current concepts. The malignant hyperthermia syndrome. N Engl J Med. 1983; 309(7):416-8. DOI: 10.1056/NEJM198308183090706. View

Denborough M, FORSTER J, LOVELL R, Maplestone P, VILLIERS J . Anaesthetic deaths in a family. Br J Anaesth. 1962; 34:395-6. DOI: 10.1093/bja/34.6.395. View

NEVINS M, Saran M, Bright M, LYON L . Pitfalls in interpreting serum creatine phosphokinase activity. JAMA. 1973; 224(10):1382-7. View

Gronert G, Thompson R, Onofrio B . Human malignant hyperthermia: awake episodes and correction by dantrolene. Anesth Analg. 1980; 59(5):377-8. View

Baudendistel L, Goudsouzian N, Cote C, Strafford M . End-tidal CO2 monitoring. Its use in the diagnosis and management of malignant hyperthermia. Anaesthesia. 1984; 39(10):1000-3. DOI: 10.1111/j.1365-2044.1984.tb08889.x. View

10.

Gronert G . Malignant hyperthermia. Anesthesiology. 1980; 53(5):395-423. DOI: 10.1097/00000542-198011000-00007. View

11.

Moyes D . Malignant hyperpyrexia caused by trimeprazine. Case report. Br J Anaesth. 1973; 45(11):1163-4. DOI: 10.1093/bja/45.11.1163. View

12.

KOLB M, Horne M, Martz R . Dantrolene in human malignant hyperthermia. Anesthesiology. 1982; 56(4):254-62. DOI: 10.1097/00000542-198204000-00005. View

13.

Byrick R, ROSE D, Ranganathan N . Management of a malignant hyperthermia patient during cardiopulmonary bypass. Can Anaesth Soc J. 1982; 29(1):50-4. DOI: 10.1007/BF03007948. View

14.

Ryan J, Donlon J, Malt R, Bland J, Buckley M, SRETER F . Cardiopulmonary bypass in the treatment of malignant hyperthermia. N Engl J Med. 1974; 290(20):1121-2. DOI: 10.1056/NEJM197405162902006. View

15.

Britt B, KALOW W . Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970; 17(4):293-315. DOI: 10.1007/BF03004694. View